Epithelioid sarcoma is a rare, malignant, soft tissue neoplasm that can be classified into proximal, distal and fibroma-like subtypes. Regardless of subtype, epithelioid sarcoma often shows morphologic and immunophenotypic evidence of epithelial differentiation. Current therapeutic strategies include surgical resection, amputation, radiation or chemotherapy, although the overall prognosis remains poor. The epidermal growth factor receptor (EGFR) is a novel therapeutic target in carcinomas. In some carcinomas, EGFR kinase domain mutations or gene amplification may correlate with response to specific inhibitors. EGFR expression has been reported in some sarcoma types, but expression, amplification and mutations have not been studied in epithelioid sarcoma. We evaluated 15 cases of epithelioid sarcoma from 14 patients for EGFR expression using immunohistochemistry, EGFR copy number aberration using fluorescence in situ hybridization and screened for mutations in the tyrosine kinase domain of the EGFR gene using direct sequencing. In all, 14 of the 15 epithelioid sarcomas (93%) showed expression of EGFR by immunohistochemistry. A majority of the cases (n ¼ 11, 73%) showed strong (2 þ to 3 þ ) and homogeneous (475% of cells) membrane staining. No amplification or polysomy of the EGFR gene or mutations of the tyrosine kinase domain of EGFR (exons 18-21) were detected. These results imply that although EGFR is expressed in most epithelioid sarcomas regardless of subtype, gene amplification and activating mutations in the tyrosine kinase domain appear to be rare or absent. Thus, the benefit of targeted therapy against EGFR in patients with epithelioid sarcoma remains to be determined.
Epithelioid sarcoma is a rare, malignant soft tissue neoplasm that was initially described by Enzinger in 1970 . 1 Epithelioid sarcoma can be divided into three distinct morphologic subtypes: distal, proximal and fibroma-like. The distal, and most common, subtype typically arises in the distal extremities of young adults, with a predilection for the wrist, hand and fingers. The proximal subtype is generally found in the groin or trunk of older adults. Morphologically and immunophenotypically, these tumors mimic features of true epithelial neoplasms insofar as they stain for low-and high-molecular weight cytokeratins, as well as epithelial membrane antigen.
Ultrastructural analysis shows evidence of epithelial and myofibroblastic differentiation. [2] [3] [4] Recently, loss of expression of INI1, a core subunit of a chromatin remodeling complex involved in transcriptional regulation, has been documented in both distal and proximal-type epithelioid sarcomas, providing a possible mechanism of tumorigenesis. 5, 6 Current therapeutic strategies use wide surgical excision, radical resection, and in exceptional cases, amputation, followed by chemotherapy and/or radiation therapy. Regardless of subtype, the overall prognosis is poor, with local recurrence observed in up to 93% of patients, metastases in 30-45% and overall 10-year survival of 42%. 7 The human epidermal growth factor receptor (EGFR) (HER) family consists of four distinct type 1 receptor tyrosine kinases and includes HER1 (ErbB-1, EGFR), HER2 (ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). On ligand binding, these receptors form homo-or heterodimers with other HER members leading to autophosphorylation and activation of downstream signaling pathways involved in cell proliferation, apoptosis and angiogenesis. Consequently, aberrant EGFR signaling has been implicated in malignant transformation and tumor cell survival, especially in carcinomas, suggesting a therapeutic role for targeted EGFR inhibitors. Specifically, small molecule tyrosine kinase inhibitors and monoclonal antibodies against EGFR represent novel therapeutic approaches in colorectal adenocarcinoma, non-small cell lung carcinoma and squamous cell carcinoma of the head and neck. [8] [9] [10] Previous studies have shown that mutations in the tyrosine kinase domain of EGFR (corresponding to exons [18] [19] [20] [21] or amplification of the EGFR gene can be used as biomarkers for response to EGFR-targeted therapy or overall survival. 11, 12 Interestingly, recent evidence suggests that EGFR expression is not unique to carcinomas but may be present in malignant bone and soft tissue tumors, with a small subset showing aberrant EGFR gene copy number and/or mutations in the tyrosine kinase domain. [13] [14] [15] [16] [17] [18] However, the expression, amplification and mutation status of epithelioid sarcoma remains to be characterized.
To analyze a potential role for EGFR-targeted therapy, we evaluated 15 cases of epithelioid sarcoma from 14 patients, including examples of all three subtypes, for EGFR expression by immunohistochemistry, gene copy number aberration by fluorescence in situ hybridization (FISH), and mutations in the tyrosine kinase domain using PCR and direct sequencing. These data show that although EGFR expression is detectible by immunohistochemistry in the majority of epithelioid sarcomas, gene amplification and kinase domain mutations are rare to absent.
Materials and methods

Case Selection
The study was carried out according to guidelines set forth by the Institutional Review Board of the University of California, San Francisco and San Francisco General Hospital. We identified, retrospectively, 15 cases of epithelioid sarcoma from 14 patients in the pathology archives at our institution. The diagnosis was based on light microscopic, clinical and immunohistochemical features according to established criteria. 19, 20 Routine immunohistochemistry for keratin, epithelial membrane antigen, CD34 and INI1 was evaluated in all cases. Clinical data were obtained from records in the Department of Orthopedic Surgery.
Immunohistochemistry
Immunohistochemistry was performed on 3-mmthick paraffin-embedded sections using EGFR pharmDx (Dako, Carpinteria, CA, USA). All cases were stained and scored according to the manufacturer's recommendations. Briefly, when more than 1% of tumor cells showed partial or complete membranous staining of any intensity, the tumor was considered positive for EGFR. Staining intensity was then quantified from 1 þ to 3 þ , with 475% of cell staining defined as homogenous.
Fluorescence In Situ Hybridization
Dual-color FISH was performed on formalin-fixed paraffin-embedded, 5-mm-thick tissue sections using Vysis LSI EGFR SpectrumOrange and CEP 7 SpectrumGreen probes (Vysis, Abbott AG, Baar, Switzerland). Each sample was deparaffinized according to standard protocol, then 10 ml of EGFR and centromere 7 (CEP7) probes were applied to the tissue, cover slipped, and sealed with rubber cement. Slides were placed in Hybrite chamber (Vysis, Abbott AG), denatured for 6 min at 72 1C and hybridized overnight at 37 1C. The slides were scored by counting the EGFR and CEP7 signals in 50 cells and the average number of signals per cell was calculated. Polysomy and gene amplification were assessed according to previous published studies. 15, 21, 22 
EGFR Mutation Analysis
All specimens were assessed to confirm that the proportion of tumor in tissue sections reached 50%. Necrotic areas were specifically avoided. Briefly, genomic tumor DNA was extracted from microdissected tumor tissue obtained from five to eight 10 mm-thick, FFPE sections using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). Polymerase chain reaction was performed with 50 ng template DNA, 0.2 mM primer concentration, and Amplitaq Gold PCR Master Mix (Applied Biosystems, Foster City, CA, USA) for a total reaction volume of 20 ml. 
Results
The clinical and pathologic characteristics of the tumors are summarized in Table 1 . The series consisted of 15 tumors from 14 patients (seven women and seven men) with a mean age of 42 years (range 20-76). The primary tumors were from: upper extremity (n ¼ 5), lower extremity (n ¼ 5), groin (n ¼ 3) and chest (n ¼ 1). One patient (patient 3) had a lung metastasis, which was also included in our analysis. Histologic subtypes included distal (n ¼ 7), proximal (n ¼ 5) and fibroma-like (n ¼ 2). By routine immunohistochemistry, all tumors (n ¼ 15) expressed either keratin or epithelial membrane antigen and eight tumors expressed both. CD34 expression was identified in nine tumors and no
In all, 14 of the 15 (93%) epithelioid sarcomas showed expression of EGFR by immunohistochemistry ( Figure 1 and Table 1 ). In patient 3, both the primary and metastasis expressed EGFR. Eleven cases (73%) showed strong (2 þ to 3 þ ) and homogenous (475% of cells) membranous staining.
FISH was evaluated on 14 cases, including the primary and metastatic lesions of case 3, and none showed amplification (EGFR:CEP7 ratio ranged from 0.93 to 1.08) or polysomy of the EGFR gene (all tumors contained two EGFR copies and two centromere seven signals, Figure 2 and Table 1 ).
In 12 tumors, the tyrosine kinase domain could be successfully sequenced. DNA of sufficient quantity or quality could not be obtained on the remaining cases. Mutation analysis of the tyrosine kinase domain (exons 18-21) of the EGFR gene was evaluated using PCR and direct sequencing. There were no point mutations, insertions or deletions detected in any case (Table 1) .
Discussion
The mainstay of therapy for epithelioid sarcoma is surgical resection and, in some cases, adjuvant chemotherapy with alkylating and/or anthracycline agents and/or radiation therapy. 23, 24 In a recent review, positive prognostic indicators in epithelioid sarcomas included age younger than 16 years, local stage of disease, negative lymph node status and complete surgical resection. 25 The high rate of local recurrence and distant metastasis observed in epithelioid sarcoma necessitates the development of improved adjuvant systemic therapies. Given the presence of morphologic and immunophenotypic features suggesting epithelial differentiation and lack of effective therapies currently available, therapeutic strategies targeting EGFR are promising. The present data indicate that although all three subtypes of epithelioid sarcoma express EGFR, kinase domain mutations and gene amplification are rare or absent. To our knowledge, this study is the first to report EGFR gene amplification and kinase mutation status in epithelioid sarcoma.
Recently, several types of bone and soft tissue tumors have been shown to express EGFR and, in some cases, also amplification of the EGFR gene or mutations in the tyrosine kinase domain. [14] [15] [16] [17] In two recent studies of bone and soft tissue neoplasms, EGFR expression was noted in approximately 20% of malignant tumors, with no expression documented in benign lesions, suggesting that EGFR is preferentially expressed in sarcomas. 14, 15 However, in general, kinase domain mutations in sarcomas are rare. 26, 27 Synovial sarcoma, like epithelioid sarcoma, shows morphologic and immunophenotypic features of epithelial differentiation. It is perhaps not surprising, therefore, that EGFR is often expressed in synovial sarcoma. 18 However, in a series of 13 synovial sarcomas, Bode et al 16 found normal EGFR gene copy numbers in all cases and missense mutations in the kinase domain in only two cases. In the present series, epithelioid sarcomas showed expression of EGFR by immunohistochemistry, including strong, homogenous staining in the majority of cases, but absence of either gene amplification or kinase domain mutations. Taken together, the above data suggest that (1) EGFR amplification and kinase domain mutations in sarcomas are rare even in those tumors with epithelial morphology or immunophenotype and (2) immunohistochemical detection of EGFR expression in these sarcomas does not reliably predict gene amplification or kinase domain mutations.
Many previous studies have shown an inconsistent correlation between EGFR protein expression and response to tyrosine kinase inhibitor therapy in other tumor types. 28 In theory, at least, targeted therapy is most effective in tumors that not only express EGFR but are dependent on EGFR signaling for growth and survival. Increased EGFR activation can arise through mutational events or gene amplification, however, constitutive activation, as observed with KIT mutations in gastrointestinal stromal tumor, is not a defining feature of mutations in the tyrosine kinase domain of EGFR. Lynch et al 29 initially have shown that mutant EGFR has enhanced epidermal growth factor-dependent activation and increased sensitivity to gefitinib in vitro. Phase II clinical trails have revealed that deletion of exon 19 and L858R mutations are major markers of response to treatment in advanced non small cell lung cancer. [30] [31] [32] In the present series of epithelioid sarcomas, no mutations or deletions were detected. These findings suggest that, based on current paradigms of assessing responsiveness to EGFRtargeted therapies in carcinomas, it is uncertain whether epithelioid sarcomas would show a meaningful response to EGFR tyrosine kinase inhibitors. Nevertheless, one study in refractory, advanced nonsmall cell lung carcinoma has shown EGFR protein expression as a biomarker predictive of better survival, 33 suggesting that EGFR expression may have at least some clinical implication in sarcomas.
Further complicating the use of EGFR status as a predictive biomarker are data from several studies in metastatic colorectal carcinoma, which show that activating mutations in KRAS are predictive of unresponsiveness to therapies with cetuximab and pantimumab, regardless of EGFR mutation or gene amplification status. 34 Recently, an in vitro study found that erlotinib-sensitive cell lines had increased expression of E-cadherin, with drug-resistant cell lines possessing high levels of delta-crystallin enhancer binding factor 1 (an E-cadherin repressor) and low levels of E-cadherin expression, suggesting that these may be potentially useful biomarkers. 35 Stat-3 activation was associated with sarcomas expressing EGFR and/or having abnormal EGFR gene copy numbers by FISH, providing a potential target for the development of novel therapies.
14 Thus, evaluation of additional biomarkers in malignant bone and soft tissue tumors, including epithelioid sarcoma, will be necessary to determine appropriate patient selection for the use of EGFR-targeted therapies.
Currently, phase II clinical trials are underway to evaluate EGFR monoclonal antibody or tyrosine kinase inhibitors in the treatment metastatic or locally advanced bone and soft tissue sarcomas (http://clinicaltrials.gov). In our series, we have shown that epithelioid sarcomas express EGFR by immunohistochemistry, but do not harbor tyrosine kinase domain mutations or increased EGFR gene copy number. Additional studies are needed to determine whether patients will benefit from the use of EGFR-targeted therapies and to further elucidate biomarkers predictive of response to therapy or clinical outcome.
